PMID- 21187495
OWN - NLM
STAT- MEDLINE
DCOM- 20110204
LR  - 20201212
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 30
IP  - 12
DP  - 2010 Dec
TI  - Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA 
      mRNA for vaccination of colorectal cancer patients.
PG  - 5091-7
AB  - BACKGROUND: Dendritic cells (DCs) are the professional antigen-presenting cells 
      of the immune system. We have demonstrated that vaccination of autologous ex vivo 
      cultured DCs results in the induction of tumor-specific immune responses in 
      cancer patients, which correlates with clinical response. Optimization of antigen 
      loading is one of the possibilities for further improving the efficacy of DC 
      vaccination. Theoretically, transfection of DCs with RNA encoding a 
      tumor-specific antigen may induce a broader immune response as compared to the 
      most widely used technique of peptide pulsing. PATIENTS AND METHODS: In this 
      clinical study, RNA transfection was compared with peptide pulsing as an antigen 
      loading strategy for DC vaccination. Patients with resectable liver metastases of 
      colorectal cancer were vaccinated intravenously and intradermally 3 times weekly 
      with either carcinoembryogenic antigen (CEA)-derived HLA-A2 binding 
      peptide-loaded or CEA mRNA electroporated DCs prior to surgical resection of the 
      metastases. All DCs were loaded with keyhole limpet hemocyanin (KLH) as a control 
      protein. Evaluation of vaccine-induced immune reactivity consisted of T-cell 
      proliferative responses and B-cell antibody responses against KLH in peripheral 
      blood. CEA reactivity was determined in T-cell cultures of biopsies of 
      post-treatment delayed type hypersensitivity skin tests. RESULTS: Sixteen 
      patients were included. All patients showed T-cell responses against KLH upon 
      vaccination. CEA peptide-specific T-cells were detected in 8 out of 11 patients 
      in the peptide group, but in none of the 5 patients in the RNA group. CONCLUSION: 
      In our study, DC CEA mRNA transfection was not superior to DC CEA peptide pulsing 
      in the induction of a tumor-specific immune response in colorectal cancer 
      patients.
FAU - Lesterhuis, W Joost
AU  - Lesterhuis WJ
AD  - Departments of Medical Oncology, Radboud University Nijmegen Medical Centre, 
      Nijmegen, the Netherlands.
FAU - De Vries, I Jolanda M
AU  - De Vries IJ
FAU - Schreibelt, G
AU  - Schreibelt G
FAU - Schuurhuis, Danita H
AU  - Schuurhuis DH
FAU - Aarntzen, Erik H
AU  - Aarntzen EH
FAU - De Boer, Annemiek
AU  - De Boer A
FAU - Scharenborg, Nicole M
AU  - Scharenborg NM
FAU - Van De Rakt, Mandy
AU  - Van De Rakt M
FAU - Hesselink, Erik J
AU  - Hesselink EJ
FAU - Figdor, Carl G
AU  - Figdor CG
FAU - Adema, Gosse J
AU  - Adema GJ
FAU - Punt, Cornelis J A
AU  - Punt CJ
LA  - eng
SI  - ClinicalTrials.gov/NCT00228189
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Cancer Vaccines)
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (RNA, Messenger)
RN  - 9013-72-3 (Hemocyanins)
RN  - FV4Y0JO2CX (keyhole-limpet hemocyanin)
SB  - IM
MH  - Cancer Vaccines/administration & dosage/genetics/*immunology
MH  - Carcinoembryonic Antigen/genetics/*immunology
MH  - Colorectal Neoplasms/immunology/*therapy
MH  - Dendritic Cells/*immunology/physiology
MH  - Epitopes, T-Lymphocyte/immunology
MH  - HLA-A2 Antigen/immunology
MH  - Hemocyanins/immunology
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - RNA, Messenger/administration & dosage/genetics/immunology
MH  - T-Lymphocytes/immunology
MH  - Transfection
EDAT- 2010/12/29 06:00
MHDA- 2011/02/05 06:00
CRDT- 2010/12/29 06:00
PHST- 2010/12/29 06:00 [entrez]
PHST- 2010/12/29 06:00 [pubmed]
PHST- 2011/02/05 06:00 [medline]
AID - 30/12/5091 [pii]
PST - ppublish
SO  - Anticancer Res. 2010 Dec;30(12):5091-7.